Tag: Survival
Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia
Improvements seen in overall survival, progression-free survival, and cancer-specific survival
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration
Disparities Evident in Treatment, Survival for Patients With Pancreatic Cancer
Lower odds of receiving key components of quality care seen for those with high overall social vulnerability index
Healthy Nutrition, Activity May Reduce Mortality Risk for Cancer Survivors
Adherence to American Cancer Society guidelines linked to lower mortality in nonsmoking survivors of obesity-related cancer
Study Looks at Recovery Potential in Comatose Patients Who Died After Halting Life-Sustaining Therapy
Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
Physical Activity Linked to Attenuation of Colon Cancer Survival Disparity
Physical activity attenuates survival disparity between patients with stage III colon cancer and matched population controls
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab
Black Patients With Cancer Still Have Higher Mortality Rates Than Whites
Relative decline seen in cancer mortality among Blacks, but they still have higher mortality rates than Whites
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6